

**REMARKS**

The specification has been amended herein to update the continuing information.

Claims 9-22, 34-36, 43 and 44 have been canceled. Cancellation of these claims is without prejudice, without intent to abandon any originally claimed subject matter, and without intent to acquiesce in any rejection of record. Applicants reserve the right to bring the canceled claims again in a related application.

Claims 1, 2, 7 and 8 have been amended to recite the subject invention with greater particularity. Specifically, these claims now recite the presence of an HCV core polypeptide. Support for this recitation can be found in the specification at, e.g., pages 18-19, bridging paragraph.

Entry and consideration of the foregoing amendments is respectfully requested.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 18-1648.

Please direct all further written communications in this application to:

Alisa A. Harbin, Esq.  
Chiron Corporation  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94662-8097.

Dated: \_\_\_\_\_

8/18/03

Respectfully submitted,

CHIRON CORPORATION  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94662-8097  
Tel: (650) 493-3400  
Fax: (650) 493-3440

By: \_\_\_\_\_

Roberta L. Robins  
Reg. No. 33,208